340B disproportionate share hospitals (DSH) in 2020 spent 2.2 times more on outpatient drugs per commercially insured patient than non-340B DSH hospitals and 2.6 times more than other types of 340B hospitals, a new drug industry-funded study shows.
The Sept. 15 study commissioned by Pharmaceutical Research and Manufacturers of America (PhRMA) was just one of several punches that critics of 340B hospitals have thrown recently. Biotechnology Innovation Organization, Community Oncology Alliance, and American Action Forum also issued studies or published articles finding fault with 340B hospitals and calling for major changes to the drug discount program.
340B disproportionate share hospitals (DSH) in 2020 spent 2.2 times more on outpatient drugs per commercially insured patient than non-340B DSH hospitals and 2.6 times more than other types of 340B hospitals, a new drug industry-funded study shows.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
